Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning.
Specifically, the company highlighted a 72.9% increase in organic sales growth during the three-month period, reaching a worldwide total sales...
Implantable CGM company Senseonics has received approval from the FDA for the non-adjunctive indication for its Eversense device.
Senseonics is only the third company to secure this indication, which allows a CGM to be used for insulin dosing in lieu of a fingerstick glucometer, though patients will still need to use fingersticks twice a day for calibration.
The company plans to go live with the...
On Friday, the FDA issued a warning to patients and providers describing the dangers of diabetes management devices and software that haven’t been assessed by the agency. These include any unapproved or unauthorized continuous glucose monitors, insulin pumps and automated insulin dosing systems, whether used as a standalone device or integrated as part of a glucose management system.
“These...
This morning Biolinq, a digital health company specializing in minimally invasive continuous glucose monitoring, raised $4.75 million in extended Series A financing. This new capital was led by JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners.
This latest funding announcement will build on the $10 million the company raised in November of 2017, bringing the total Series A capital to...
On Friday, Senseonics, maker of the implantable continuous glucose monitoring system Eversense, announced a new program geared towards patients with high-deductible insurance plans or plans that don’t cover the full cost of the CGM.
The new program, called Eversense Bridge, charges patients $99 for the Eversense CGM system, in addition to the cost of the sensor placement by their provider....
This morning Senseonics, an implantable glucose sensor company, announced that data from its Eversense continuous glucose monitor will be integrated into the Glooko diabetes management platform.
This means that users of the Eversense CGM and app will now be able to sync it with the Glooko online platform and app, and be able to see historical blood glucose-related data as well as get updates...
For folks managing their diabetes with Dexcom, Siri can now answer one more question: What is my glucose level? This morning Dexcom announced a slew of new companion app features for the Dexcom G6 continuous glucose monitoring system, including the ability for Siri to read a user’s glucose level out loud and display graphs directly on the lock screen.
The app, which was released in 2018, will...
Ascensia Diabetes Care, the Swiss tech company originally formed a few years ago from a merger of Bayer Health’s diabetes division and Panasonic Healthcare, is officially moving into the CGM space via a partnership with Huzhou, China-based Zhejiang POCTech.
In the short term, the partnership will put an Ascensia-branded version of POCTech’s CE-Marked CGM in several markets by the end of the year...
Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM.
The launch adds a long-awaited feature for US users that’s been available for some time in Europe: users will be able to scan their sensors with an app on their smartphone — and see their latest reading —...
Diabetes is a costly chronic condition, and according to the International Diabetes Federation affects at least 425 million people worldwide. As such, it’s little surprise that an increasing number of digital health companies have spotted an opportunity to help patients manage and control their disease.
In fact, that opportunity led the total revenue digital diabetes market to triple in 2017 to $...
